Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results
Robert E. Coleman(University of Sheffield), Nigel Bundred(Manchester Academic Health Science Centre), Antonio Llombart‐Cussac(MedSIR (Spain)), H.P. Sleeboom(Unknown), Outi Paija(Turku University Hospital), N. Davidson(Broomfield Hospital), Antonio Frassoldati(University of Ferrara), John Forbes(University of Limerick), Holger Eidtmann, Richard de Boer(Western Hospital), Carlos H. Barrios(Eastern Cooperative Oncology Group), N Martin(Novartis (United States)), Gϋnter von Minckwitz(German Breast group), Patrick Neven(KU Leuven), Ankur Modi(Novartis (United States)), Ian Campbell(Waikato Hospital)
Cited by 337
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k